Cargando…
Ruxolitinib improves symptoms and quality of life in a patient with systemic mastocytosis
BACKGROUND: Systemic mastocytosis is a clonal myeloproliferative neoplasm associated with constitutional symptoms from mast cell mediated chemical and cytokine release. According to the literature, Ruxolitinib, a JAK1/JAK2 inhibitor, has been shown to reduce symptoms related to proinflammatory cytok...
Autores principales: | Yacoub, Abdulraheem, Prochaska, Lindsey |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743131/ https://www.ncbi.nlm.nih.gov/pubmed/26855781 http://dx.doi.org/10.1186/s40364-016-0056-5 |
Ejemplares similares
-
A 26-Year-Old Female with Systemic Mastocytosis with Associated Myeloid Neoplasm with Eosinophilia and Abnormalities of PDGFRB, t(4;5)(q21;q33)
por: Brown, Laura E., et al.
Publicado: (2016) -
The role of the clinical and psychological symptoms of mastocytosis in the patient’s quality of life
por: Spolak-Bobryk, Natalia, et al.
Publicado: (2021) -
Cutaneous and Gastrointestinal Symptoms in Two Patients with Systemic Mastocytosis Successfully Treated with Omalizumab
por: Lieberoth, Sofie, et al.
Publicado: (2015) -
Indolent systemic mastocytosis in a patient with ileocolitis
por: Chrysakopoulos, Georgios, et al.
Publicado: (2014) -
Systemic mastocytosis – a diagnostic challenge
por: Lladó, Ana Cristina Amorim Oliveira Gaia, et al.
Publicado: (2014)